LC/MS-QToF Profiling, Anti-Diabetic and Anti-Adipogenic potential of Divya MadhuKalp: A Novel Herbo-mineral Formulation

Acharya Balkrishna¹ Alpana Joshi^{1 2}, Subrata K. Das^{1 3*}, Laxmi Bisht¹, Sachin Sakat¹, Vinamra Sharma^{1 4}, Niti Sharma¹, Khemraj Joshi¹, Sudeep Verma¹, Vinay K Sharma¹, and CS Joshi¹.

Author's Affiliation:

¹Drug Discovery and Development Division, Patanjali Research Institute, NH-58, Haridwar-249405, India.

²Department of Agriculture & AgriInformatics, School of Biological Engineering & Sciences Shobhit Deemed University, Meerut-250110, India.

³School of Medical science and Technology, IIT Kharagpur- 721302, India.

⁴Amity Institute of Indian System of Medicine, Amity University, Noida- 201313, India.

* Corresponding author

E-mail: subratakdas09@gmail.com

Abstract

The incidence rate of diabetes mellitus is increasing worldwide. Herbal formulations have recently gained importance as an alternative therapeutic option in controlling diabetes without causing any side effects. In the present study, we have demonstrated maintenance of glycemie homeostasis and anti-adipogenic potential of a herbo-mineral formulation Divya MadhuKalp (DMK). Initially, we evaluated the presence of bioactive compounds in DMK using LC/MS-QToF analysis. In-vitro analysis of DMK in L6 (skeletal muscle) cells showed a significant increase in cellular glucose uptake. Similarly, a human equivalent dose of DMK significantly reduced blood glucose level in normoglycemic and oral glucose tolerance rat model. DMK extract also inhibited formation of advanced glycation end product and showed anti- α -glucosidase activity. Further analysis of DMK in 3T3 L1 pre-adipocytes demonstrated anti-adipogenic activity through reduction in intracellular lipid accumulation and triglyceride contents along with downregulation of major adipogenic transcriptional factors (PPAR- γ and C/EBP α) and, adipocytes marker genes (LPL, AP2 and adiponectin). In conclusion, DMK exhibited anti-diabetic and anti-adipogenic activities by synergistic effect of its bioactive compounds and can be considered as a potent herbo-mineral formulation for treating metabolic diseases.

Keywords: Anti-diabetic, Adipogenesis, Herbo-mineral formulation, Divya MadhuKalp, Gene expression.

Introduction

Diabetes mellitus (DM) is a chronic metabolic disorder that has profound effects on patient's quality of life in terms of health and socio-economic levels. According to International Diabetes Federation's (IDF) projections, approximately 693 million people will be diagnosed with DM by year 2045¹. DM is characterized by abnormally high blood glucose resulting from defective metabolism of carbohydrates, lipids and proteins. Long-term pathophysiological complications associated with DM are cardiovascular diseases, nephropathy, neuropathy and retinopathy. During hyperglycemic condition, there is also development of advanced glycation-end products (AGEs) as a consequence of protein glycation. AGEs are the possible causal factor lead to the development of diabetes related complications. Currently, the core objective of diabetes treatment is to maintain the normal blood glucose levels and, to prevent or delay its metabolic complications.

Obesity is the excessive accumulation of fat or adipose tissue in the body². It is a major risk factor for the development of type 2 diabetes mellitus (DM). Adipogenesis involves differentiation of pre-adipocytes into mature adipocytes and is regulated by two major adipogenic transcription factors namely, Peroxisome proliferator-activated receptor γ (PPAR γ) and CCAAT/enhancer binding protein α (C/EBP α) and downstream induction of adipocyte-related genes including, adipocyte protein 2 (AP2), lipoprotein lipase (LPL), adiponectin etc.^{3,4,5}.

Medicinal plants have great importance to human health and communities. The medicinal value of these plants typically results from the presence of many bioactive compounds. In contrast to synthetic drugs based on single molecule, many bioactive compounds of poly herbal formulation exert their beneficial effects through the additive or synergistic action acting at single or multiple target sites associated with a physiological process^{6,7}. Unlike, synthetic drugs,

which may induce unwanted side-effects, natural herbal formulations tend to show similar efficacy with minimal to no side-effects and cost effectiveness^{6, 7, 8}. In traditional Indian medicine system, numerous herbal and herbo-mineral formulations have been used for treating various diseases, but their scientific evidence is still lacking. Divya MadhuKalp (DMK) is an Ayurvedic herbo-mineral formulation has been extensively used in clinical practices for managing blood glucose levels during onset of DM. The DMK comprises of eight herbs and one minerals-rich organic component in specific proportion to make complex bioactive formulation (Table 1). The ingredients are; *Momordica charantia*⁹; *Picrorhiza kurroa*¹⁰; *Swertia chiraita*¹¹; *Azadirachta indica*¹²; *Trigonella foenum-graecum*¹³; *Syzygium cumini*¹⁴; *Withania somnifera*¹⁵; *Aconitum heterophyllum*¹⁶ and *Shilajeet* (Asphaltum)^{17,18}. The ingredients in DMK have been used for diabetic therapy in ancient Indian Ayurvedic medicinal system. In order to explore the pharmacological mechanism of poly herbal extracts, accurate characterization of the bioactive compounds is very essential. Moreover, the quality control is very important factor in discovery of a new drug. LC/MS-QToF technology is most appropriate analytical method for the full characterization and quality control of poly herbal extract¹⁹. DMK associated herbal ingredients have been found to be rich in secondary metabolite compositions such as, phenolics, terpenes, and nitrogen containing compounds. These active bio-molecules play an important role in carbohydrate and lipid metabolism leading to efficient management of diabetes progression and associated complications^{20, 21}.

In the present study, we performed the chemical profiling by LC/MS-QToF analysis and determined the anti-diabetic and anti-adipogenic potential of the herbo-mineral extract of DMK using *in vitro* and *in vivo* models.

Material and Methods

Experimental Material

Divya MadhuKalp (DMK) was sourced from Divya Pharmacy, Haridwar, India. Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), Insulin and bovine serum albumin (BSA), MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide], IBMX (3-isobutyl-1-methylxanthine), dexamethasone were obtained from (ThermoFischer, USA). 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxy-d-glucose (2-NBDG) was purchased from Invitrogen (Carlsbad, CA, USA). Trypsin-EDTA solution was purchased from GIBCO BRL (Grand Island, NY, USA). Sterile 96 well plates were obtained from Tarsons India Pvt. Ltd. (Kolkata, India). Oil-Red-O, metformin, α -glucosidase, acarbose, p-nitrophenyl glucopyranoside, aminoguanidine, glibenclamide, D-glucose, and sodium carboxy methyl cellulose were purchased from Sigma-Aldrich (USA). The glucose monitoring system, measurements strips (Life Scan, Switzerland) and sodium chloride injection I.P. 0.9 % w/v (Infutec Healthcare Ltd. India) was procured locally. All other chemicals and reagents used were of the highest commercial grade. HPLC grade reagents of analytical grade toluene, ethyl acetate, formic acid, Gallic acid Vanillic Acid, Caffeic acid, Trigonelline, Adenosine, Rutin Quercetin Picriside I Pcoside II, Trans-Cinnamic acid and Apigenin were obtained from the Sigma-Aldrich, India.

Experimental Animals and Reagents

Male Wistar rats (160-180 g) were procured from Liveon Biolabs Pvt. Ltd., Bengaluru, India. Animals were housed in polypropylene cages in controlled room temperature 22 ± 1 °C and, relative humidity of 60-70 % with 12:12 h light and dark cycle in a registered animal house (1964/PO/RC/S/17/CPCSEA). The animals were supplied with standard pellet diet (Golden Feed, New Delhi, India) and sterile water *ad libitum*. The animal experimental study protocol for this work was approved by the Institutional Animal Ethical Committee of Patanjali Research Institute, India (IAEC protocol number- PRIAS/LAF/IAEC-003) and all the experiments were performed following relevant guidelines and regulations.

Preparation of Divya MadhuKalp (DMK) Extract

DMK (20 g) and its individual constituents were suspended separately in 300 ml of 70 % aqueous ethanol. The suspension was refluxed for 6 h at 45 °C and, filtered through Whatman filter no-41. The filtrates were evaporated at 45 °C under reduced pressure in a rotary evaporator. The final dried samples were stored in desiccator at room temperature.

High-Performance Liquid Chromatography (HPLC) Analysis

The extract of DMK was diluted in 50 % methanol (1 mg/ml) and subjected to HPLC analysis. Waters binary HPLC system (Waters Corporation, Milford, MA, USA), equipped with, column oven, auto-sampler (Waters 2707) and, photodiode array (PDA) detector (Waters 2998) was used for the analyses. A reversed phase C18 analytical column (4.60×250 mm, 5 µm particle size; Sunfire, Waters, USA) was utilized at 30 °C column temperature. The injection volume was

10 μ l (DMK) and 10 μ l (standard mix) at different concentration. The chromatograms were acquired at 230 nm according to the absorption maxima of the analyzed compounds. Each compound was identified by its retention time (RT) and, by spiking with standards under the same conditions. The identities of constituents were also confirmed with a photodiode array (PDA) detector by comparison with ultraviolet (UV) spectra of standards in the wavelength range of 210–650 nm.

Liquid Chromatography Mass Spectroscopy-Quadrupole Time-of-Flight (LC/MS-QToF) Analysis

Twenty milliliter of methanol: water (60:40) was added in 200.3 mg of powdered Divya MadhuKalp (DMK) and sonicated for 30 min. Then this solution was centrifuged for 5 min at 10,000 rpm and filtered through 0.22 μ m nylon filter. The extract was used for LC/MS analysis. The LC/MS-QToF instrument was equipped with an ESI ion source operating in a positive and negative ion mode. A mass range of 50-1000 Da was set with a 0.2 s scan time. The main working parameters for mass spectrometry were set as follows, ionization type-ESI, mode-MS^E, acquisition time-45 min, mass range (m/z) 50–1000 m/z , low collision energy-6 eV, high collision energy 20-40 eV (ramp), cone voltage-40 V, capillary voltage-1 kV (for positive ion mode) (Figure 1A), capillary voltage-2 kV (for negative ion mode) (Figure 1B), source temperature-120 °C, desolvation temperature-450 °C, cone gas flow-50 L/h, desolvation gas flow-900 L/h. Mass was corrected during acquisition, using an external reference (Lock-Spray) consisting of 0.2 ng/ml solution of leucine enkephalin infused at a flow rate of 10 μ l/min via a lock-spray interface, generating a reference ion for the positive ion mode [(M + H)⁺ + m/z 556.2766] and for the negative ion mode [(M - H)⁺ m/z 554.2620] to ensure mass accuracy.

during the MS analysis. The Lock-Spray scan time was set at 0.25 s with an interval of 30 s. Analysis was performed on a Waters Xevo G2-XS QToF equipped with Acquity UPLC-I Class and Unifi software. Separation was carried out using Acquity UPLC HSS-T3 column (100 × 2.1 mm, 1.7 µm). The column was maintained at 40 °C throughout the analysis, and sample temperature was kept at 20°C. The elution was carried out at a flow rate of 0.4 ml/min using gradient elution 0.1 % formic acid in water (mobile phase A) and 0.1 % formic acid in acetonitrile (mobile phase B). Solvent gradient program was 95 %-90 % of the mobile phase A during 0-5 min, 90 %-80 % A during 5-10 min, 80 %-60 % A during 10-20 min, 60 %-40 % A during 20-30 min, 40 % A during 30-45 min, 40 %-95 % A during 45-46 min, followed by 95 % A during 46-50 min. A total of 2 µl of the test solution was injected for the screening and the chromatograph was recorded for 45 min.

Cell lines and Culture condition

Mouse 3T3-L1 pre-adipocytes and rat skeletal muscle L6 cell lines were procured from ATCC licensed repository, National Centre for Cell Sciences (NCCS), Pune, India. Cells were cultured in 96 well culture plates with complete medium (high glucose Dulbecco's Modified Eagle Medium, 10 % fetal bovine serum (FBS) and 50 µg/ml penicillin/streptomycin).

In-vitro Cytotoxicity Assay

Cells (3T3-L1 and L6) were seeded in a 96-well plate (5×10^3 cells/well) and incubated at 37 °C, 5 % CO₂ with complete medium for 24 h. After 24 h, the medium was changed to complete medium supplemented with DMK extract and its constituents at various concentrations for 24 h. MTT solution (5 mg/ml in PBS) was then added to the plate (10 µl/100 µl

medium/well) and incubated for 4 h at 37 °C. The resultant formazan product was dissolved in DMSO (200 µl/well) and absorbance was measured at 492 nm by EnVision Multimode Plate Reader (Perkin Elmer, USA).

Glucose Uptake in L6 cells

L6 cells were cultured in a humidified atmosphere of 5 % CO₂ at 37 °C for 2 days to grow up to 70 % confluency. The cells were dissociated with Trypsin-EDTA solution (GIBCO BRL, Grand Island, NY, USA) and, seeded in 96 micro well plates (Tarsons India Pvt. Ltd., Kolkata, India). After two days incubation, cells were starved with serum and glucose free DMEM media for 2 h. Cells were treated with different concentrations of DMK extract (0-250 µg/ml) and single concentration (62.5 µg/ml) of ten individual extracts (DMK and its nine components) in glucose free media containing 0.05 % FBS and insulin (100 nM). 2-NBDG was added (50 µg/ml) in the culture, incubated at 37 °C for 30 min. Metformin (Sigma-Aldrich, USA) was used as a positive control at the concentration of 100 µM. After incubation, cells were harvested, washed thrice with PBS and, the resultant fluorescence was measured with flow cytometer (Amnis® Imaging Flow Cytometers, Millipore, USA). Cells taking up 2-NBDG displays fluorescence with excitation and emission at 485 nm and 535 nm, respectively, and, measured in appropriate channel. For a given measurement, data from 8,000 single cell events was captured using flow cytometry.

Alpha-Glucosidase Activity

The effect of DMK extracts on alpha-glucosidase activity was determined using alpha-glucosidase (Sigma-Aldrich, US) from *Saccharomyces cerevisiae*. Acarbose was used as a positive control. The enzyme (0.33 µg/ml) was pre-incubated with the extracts at different concentrations for 10 min. The reaction was initiated by adding 3 mM p-nitrophenyl glucopyranoside (pNPG) and the reaction mixture was incubated at 37 °C for 20 min. The reaction was terminated by adding 0.1 M Na₂CO₃⁺ solution (500 µl). The alpha-glucosidase activity was determined by measuring the yellow-colored para-nitrophenol released from pNPG at 405 nm (EnVision Multimode plate reader, Perkin Elmer, USA). The results were expressed as the percentage of the blank.

Anti-Glycation Activity

The anti-glycation activity of DMK extract was determined using the bovine serum albumin (BSA) (Hi-Media, India) following the method described with slight modification²². BSA glycation reaction was carried out by incubating 1 ml of 50 mg/ml BSA in 0.1 M phosphate buffer (pH 7.4) and, 0.5M dextrose monohydrate containing 5 mM sodium azide as bacteriostatic at 37 °C for 1- 4 weeks with various concentrations of the extracts. Aminoguanidine (Sigma-Aldrich, USA) was used as a positive control. The BSA glycation was monitored at 370/440 nm by using EnVision Multimode Plate Reader (Perkin Elmer, USA).

Dose Selection and Preparation of Test Formulation

The human equivalent dose of DMK for the rat experiments was estimated through body surface area²³. The human recommended dose of DMK is 500-1000 mg twice a day. Therefore,

maximum equivalent dose for rat was estimated as 200 mg/kg/day, considering dose conversion factor of 6.2²³. The powdered form of DMK (Batch no-MNVE004) was suspended in 0.25 % Na-CMC, triturated to form uniform suspension and used for the *in-vivo* experiments.

Assessment of Hypoglycemic Activity in Normal Rats

The acute effect of single dose exposure of DMK was evaluated for hypoglycemic potential in normal animals according to the modified method²⁴. All the animals were fasted for 14-16 h before commencing the experiment. Fasting blood glucose levels (0 min) were measured using glucose testing strips and, randomized into different groups of eight animals each. Control animals were treated orally with 0.25 % Na-CMC. The standard drug Glibenclamide (GLB) or Test sample DMK was administered orally to animals at 10 or 200 mg/kg doses, respectively. Blood glucose level was measured at 30, 60, 90 and 120 min after the drug treatment using tail snip method.

Assessment of Hypoglycemic Activity by Oral Glucose Tolerance

Test (OGTT) in normal rats

Oral Glucose Tolerance Test was performed on 14-16 h fasted rats²⁵. Control, reference control and, treatment animals administered orally with 0.25 % Na-CMC, GLB (10 mg/kg) and DMK (200 mg/kg), respectively to assess the hypoglycemic activity of DMK. After 30 min of drug treatment, all the animals treated orally with D-Glucose at a dose of 3 g/kg; and blood glucose levels were measured at different time points (30, 60, 90 and 120 min).

239

240 **3T3-L1 Adipocyte Differentiation**

241 Mouse 3T3-L1 cells were grown in complete media and upon confluency, the media were
242 replaced with adipogenic differentiation cocktail media (MDI) containing Insulin (10 µg/ml), 0.5
243 mM IBMX, 1 mM dexamethasone on the following day⁴. At the same time, cells were treated
244 with various concentrations of DMK extract (0-250 µg/ml) and single concentration (250 µg/ml)
245 of ten extracts (DMK and its nine components), except *Trigonella foenum-graecum*, *Tf*
246 (62.5µg/ml). The culture was further incubated at 37 °C, 5 % CO₂ for 2 days. After that, the
247 induction media were changed with differentiation media (DMEM + 10 % FBS + 10 µg/ml
248 Insulin) for 6 days. At this point media was changed every alternate day. Adipocytes were
249 treated with DMEM media (DMEM + 10 % FBS) for 2 days to mature the oil droplets. The
250 extent of differentiation was determined on day 10 by Oil Red O staining.

251

252 **Oil Red O Staining**

253 Oil Red O staining on day 10 after induction determined intracellular lipid accumulation.
254 After removal of culture media, the cells were washed twice with PBS, fixed with 10 % formalin
255 and, stained with Oil Red O (six parts 0.6 % Oil red O dye in isopropanol and four parts water)
256 for 30 min. After three rinses with distilled water and, once with 60 % isopropanol, these cells
257 were photographed under the bright field microscope (Primover, Zeiss, USA). To quantify the
258 lipid accumulation, lipid and Oil Red O were dissolved in isopropanol and, absorbance was
259 measured by a microplate spectrophotometer at 495 nm (EnVision Multimode plate reader,

Perkin Elmer, USA). The percentage of Oil red O stained material relative to control wells was calculated.

Quantification of Triglyceride Deposition

Intracellular triglycerides (TG) content was measured using Triglyceride Colorimetric Assay Kit (Cayman chemicals, USA) according to the manufacturer's protocol. In brief, cells were washed with PBS, harvested by trypsinization and, re-suspended in PBS. The cell suspension was homogenized by sonication, the enzymatic reaction was carried out for 15 min at room temperature and finally, the absorbance (540 nm) was taken using plate reader (EnVision Multimode plate reader, Perkin Elmer, USA).

Quantitative Real-Time PCR Analysis

Total RNA was extracted (RNeasy Mini Kit, Qiagen, USA) from mouse 3T3-L1 pre-adipocytes at the desired 4th day of adipogenic differentiation, treated with various concentrations (0-250 µg/ml) of DMK. First strand cDNA was synthesized using 1 µg of total RNA using manufacturer protocol (Verso cDNA Synthesis Kit, ThermoFischer, USA). Selected genes were amplified and, quantified by performing PCR reaction using Brilliant II SYBR® Green QPCR Master Mix (Agilent Technologies, USA). The primer sequences for PCR analysis were as follows:

PPAR γ	(sense)	TTCAGCTCTGGGATGACCTT,	(antisense)
CGAAGTTGGTGGGCCAGAAT;	C/EBP α	(sense)	GTGTGCACGTCTATGCTAAACCA,
(antisense)	GCCGTTAGTGAAGAGTCTCAGTTTG;	LPL	(sense)
GGCCAGATTCATCAACTGGAT,	(antisense)	GCTCCAAGGCTGTACCCTAAG;	
Adiponectin (sense)	GTTGCAAGCTCTCCTGTTCC,		(antisense)

ATCCAACCTGCACAAGTTCC; AP2 (sense) CATCAGCGTAAATGGGGATT, (antisense) TCGACTTTCCATCCCACTTC, and, GAPDH (sense) AAGAAGGTGGTGAAGCAGGCATC, (antisense) CGAAGGTGGAAGAGTGGGAGTTG. PCR conditions were as follow: 1 cycle of 50 °C for 10 min and 95 °C for 5 min, 35 cycles of 95 °C for 10 s, 60 °C for 30 s and 72 °C for 30 s. Relative gene expression was expressed as relative mRNA level compared with the control, was calculated after normalization to GAPDH (house-keeping gene) following the $2^{-\Delta\Delta CT}$ method.

Statistical Analysis

All experimental data are presented as the mean $\pm$ standard error of the mean (SEM). Statistical analysis was done using GraphPad Prism version 7.0 software (La Jolla, CA, USA). A one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison t-test was used to calculate statistical difference. Statistical significance was considered at * $p < 0.05$ or ** $p < 0.01$.

Results

Identification of Marker Compounds of Divya MadhuKalp (DMV)

A detailed phytochemical profiling of DMK was performed using LC/MS-QToF analysis. A total 139 compounds have been identified. The chromatogram of the hydroalcoholic extract from DMK was displayed in **Figure 1** (A-positive ion mode and B-Negative ion mode) and LC/MS data of the identified compounds with their retention time, calculated m/z value and responses (frequency) were provided in **supplementary Table 1**. Identified compounds belonged to various classes including Flavonoids, Phenolic Acid, Alkaloids, Tri-terpenoids,

Steroida, Fatty Acid, Amino Acids, Other Organic acids, Iridoids and Vitamins. The major bioactive compounds were tabulated with their classification, therapeutic effect and references [26-104] (**Table 2**). The bioactive compounds have diverse therapeutic potential including anti-diabetic and anti-obesity activities. Altogether, eleven different phytochemicals were identified by HPLC in the DMK extract namely, Gallic acid Vanillic Acid, Caffeic acid, Trigonelline, Adenosine, Rutin Quercetin Picric acid, Picric acid II, Trans-Cinnamic acid and Apigenin (**Figure 2 and Table 3**).

Effect of Divya MadhuKalp on Cell Viability

Treatment of 3T3-L1 cells with DMK and other extracts showed significant loss of cell viability at relatively high doses of 750 and 1000 µg/ml except *Trigonella foenum-graecum* (Tf). DMK and all the other constituent extracts were found to be non-toxic between the tested concentrations of 187.50 and 375 µg/ml in the 3T3-L1 cells. Tf treated 3T3-L1 cells showed ~50% loss of cell viability at the high concentration of 93.75 µg/ml (**Figure 3**). L6 cells showed similar pattern of cell viability (data not shown).

Effect of Divya MadhuKalp on Glucose Uptake in L6 Cells

Efficacy of DMK and its nine components on cellular glucose uptake was studied in L6 cells using 2-NBDG, a fluorescent glucose analog. Insulin stimulated control L6 cells (Untreated) showed a 3 fold increase in the glucose uptake as compared to the insulin untreated (basal) cells. Co-treatment of the insulin treated L6 cells with DMK at the tested concentrations of 31.25, 62.5, 125 and, 250 µg/ml showed 3.6, 6.2, 7.3 and 7.8 fold increase in glucose uptake as compared to vehicle control under insulin stimulated condition (**Figure 4A**). Highest glucose

uptake by the insulin stimulated L6 cells was measured at 250 µg/ml of DMK which was similar to reference drug Metformin (8.2 fold). Based on the dose response study, nine components of DMK were also screened independently at the concentration of 62.5 µg/ml for their glucose uptake potential. All the extracts showed significant increase in glucose uptake as compared to the vehicle control. Increase in glucose uptake were observed as 7, 3.8, 5, 5, 7.8, 7.5, 4.4, 7, 7.4, and 7.4 folds in DMK, *Mc*, *Pk*, *Sc*, *Ai*, *Tf*, *Syc*, *Ws*, *Ah* and *Sh*, respectively (**Figure 4B**).

Flow cytometry analysis of treated cells showed changes in the fluorescence intensity of 2-NBDG, with respect to untreated cells. Increase in 2-NBDG intensity moved the peak maxima toward right in comparison to vehicle control and, this change in 2-NBDG intensity represents the glucose uptake potential of cells. **Figure 4C** showed the comparative glucose uptake of treated and untreated cells (Vc). These results demonstrated that DMK as well as its components are capable of stimulating glucose uptake under *in-vitro* conditions.

Effect of Divya MadhuKalp on α -Glucosidase Activity and Advanced Glycation End Product (AGE) Formation

Inhibitors of α -glucosidase have been observed to delay glucose absorption by preventing carbohydrates digestion. In order to investigate the inhibitory effect of DMK extract, an *in-vitro* α -glucosidase inhibition test was performed. DMK displayed inhibitory activity for α -glucosidase enzyme with an IC₅₀ value of 28.74 µg/ml. Acarbose was used as a positive reference control in a parallel experiment. DMK exhibited 55 % inhibition at 30 µg/ml and 97 % at 100 µg/ml concentration, respectively (**Figure 5A**).

The anti-glycation capacities of the DMK extracts was evaluated by the inhibition of the AGEs formation in the BSA/glucose system up to 4 weeks. The extract inhibited AGEs in a time and dose dependent manner. At 1st week, the extract exhibited no significant inhibition where as from 2nd -4th week significant inhibitory capacity were observed at all concentrations compared to 1st week. However, at 4th week inhibition was saturated with the extract of DMK. At 2nd -4th week a clear dose dependent (0.1 to 30 mg/ml) inhibition was observed. DMK exhibited a robust inhibitory response on AGEs formation with an IC50 value of 2.3 mg/ml, 1.4 mg/ml and 1.5 mg/ml whereas the positive control Aminoguanidine (AG) in the parallel experiments demonstrated the IC50 of 0.18 mg/ml, 0.08 mg/ml and 0.14 mg/ml in 2nd, 3rd and 4th week respectively (**Figure 5B**).

Effect of Divya MadhuKalp on Blood Glucose Levels in Rats

DMK was tested for its anti-diabetic properties in animal model (Wistar rats) of hypoglycemia at the human equivalent dose of 200 mg/kg. Oral treatment with DMK (200 mg/kg) showed significant ($p<0.01$) reduction in blood glucose level (BGL) at 120 min as compared to the vehicle control treated animals (**Figure 6A**). Positive control, Glibenclamide at the tested concentration of 10 mg/kg exhibited significant decrease in BGL at 60 ($p<0.01$), 90 ($p<0.01$) and 120 min ($p<0.01$) as compared to the vehicle control animals.

DMK was also tested for the Oral Glucose Tolerance Test (OGTT) in rats. Animals exhibited mean basal BGL of 79.6 ± 0.2 mg/dL after 12-14 h fasting. Vehicle-treated control animals dosed with D-glucose showed prominent ($p<0.01$) rise in BGL after 30 min, thereafter it returned to its baseline in 120 min (**Figure 6B**). Oral treatment of DMK at 200 mg/kg to glucose dosed animals showed significantly decreased BGL at 30 ($p<0.05$) and 90 min ($p<0.05$) as

compared to control animals at these respective time points. In fact, the rate of BGL rise was also attenuated by DMK treatment, substantiating its glucose lowering properties in the intact animal systems. The standard of care drug, GLB at 10 mg/kg significantly lowered elevated BGL at 30 (p<0.01), 60 (p<0.01), 90 (p<0.05) and 120 min (p<0.01), as well (**Figure 6B**).

Effects of Divya MadhuKalp on Adipocyte Differentiation

Anti-adipogenic activity of DMK and its nine constituents were evaluated in 3T3 L1 cells. Differentiation of pre-adipocytes into mature adipocytes was identified through the intracellular accumulation of lipid droplets in mature adipocytes, and quantified by Oil red O staining and, microscopy. In our study, 3T3 L1 cells treated with DMK extract gradually showed reduction of lipid droplets in a dose dependent manner (36.1% (31.2 µg/ml), 55.5 % (62.5 µg/ml), 67.9 % (125 µg/ml) and 80 % (250 µg/ml) (**Figure 7A and 7B**). Differentiated 3T3–L1 cells (vehicle control) showed enhanced lipid accumulation (~65 %) when compared with the pre-adipocytes (UI). Investigation of the anti–adipogenic potential of individual components of DMK revealed the *Tf* (67.4 %), *Ws* (65.4 %) and *Syc* (50.55 %) to exhibit significant inhibition in lipid accumulation as compared to the vehicle control. Microscopic observations also revealed that cells treated with DMK, *Tf*, *Ws* and *Syc* maintained fibroblastic shape and contained less lipid droplets (**Figure 7C and 7D**).

Intracellular quantification of the triglycerides content on day 10 of adipogenic differentiation showed significant reduction in triglycerides accumulation following DMK treatment in a dose–dependent manner [62.5 µg/ml (21.1 %), 125 µg/ml (32.26 %) and 250 µg/ml (43.85 %)] (**Figure 7E**). Taken together, these finding strongly suggest that DMK inhibits adipogenesis differentiation in 3T3 L1 pre–adipocytes.

Effect of Divya MadhuKalp on Expression of Adipogenic Transcription Factors and Marker Genes

Influence of DMK on the mRNA expressions of transcription factors; PPAR γ and C/EBP α involved in adipocyte differentiation was studied in 3T3 L1 cells. In our study, the expression level of PPAR γ was inhibited at the DMK concentrations of 125 μ g/ml (3.2 fold) and 250 μ g/ml (4.1 fold), respectively. Similarly, C/EBP α showed 3.53 and 4.7 fold inhibition in expression level at the same tested DMK concentrations (**Figure 8A & 8B**).

Further downstream gene expression profiling of the adipocyte specific genes such as adiponectin, LPL and AP2 was done in DMK treated 3T3 L1 cells. Downregulation of LPL gene was noted with 2, 5 and 5.23 fold at 62.5, 125 and 250 μ g/ml concentrations, respectively (**Figure 8C**). Similarly, expression of AP2 was inhibited significantly by all tested concentrations of DMK, showing a 6, 7.6 and 12.8 fold inhibition effect at 62.5, 125 and 250 μ g/ml concentrations, respectively (**Figure 8D**). The fold inhibition in the expression level of adiponectin was found at 125 μ g/ml (1.2 fold) and 250 μ g/ml (2 fold) concentrations of DMK compared to untreated cells (**Figure 8E**). These results suggested that DMK regulated the lipid accumulation by downregulating expression of adipogenic genes, resulting in the prevention of adipogenesis.

Discussion

Plants remain as an important source of therapeutic material since antiquity. Several studies have been conducted to find a safe and effective therapy to treat diabetes in traditional medicine system^{105,106,107}. Standardization of polyherbal formulation is required to evaluate the quality and safety of herbal product to use it as an authentic drug^{19,108}. In the present study, DMK extract was evaluated to identify the presence of bioactive chemical compounds using LC/MS analysis. The result showed that total 139 compounds including flavonoids, phenolic acids, terpenoids, phytosteroids, fatty acids, iridoid glycosides, vitamins and amino acids are present in the extract. The analysis also revealed that flavonoids and organic acids are the major compounds occurring in DMK extract. Therefore, major therapeutic activities might come from the flavonoids and organic acids present in the DMK.

Diabetes is characterized by high blood sugar levels, therefore lowering blood sugar levels in hyperglycemic state is the main treatment method in diabetes and its associated complications. Skeletal muscle is the major target site for insulin stimulated glucose uptake and plays an important role in postprandial glucose regulation¹⁰⁹. In the present study, we observed that DMK enhanced glucose uptake significantly in skeletal muscle (L6) cells, even the lowest tested concentration (31.25 µg/ml) showed 3.6 fold increase in cellular glucose uptake as compared to vehicle control in insulin–stimulated condition. Hypoglycemic activity of DMK was also evaluated in normoglycemic animals. The results demonstrated that a significant reduction in blood glucose level at human equivalent (200 mg/kg) dose of DMK. In addition, OGTT was used to detect the impaired glucose tolerance that represents pre-diabetic and diabetic conditions. Our results displayed that the treatment of DMK at human equivalent dose prominently modulated glucose tolerance in normal rats by minimizing the blood glucose level (BGL) peak

post glucose loading. These studies indicated that the increased glucose uptake or hypoglycemic effect in the target cells or tissue due to the synergistic effect of various bioactive compounds present in DMK which probably stimulated the pancreatic β -cells to produce insulin and its sensitization or possesses an insulin like or extra-pancreatic mechanism of action (Table 3).

One of the therapeutic approaches to regulate postprandial glucose level is inhibition of carbohydrate hydrolyzing enzymes, such as α -glucosidase⁴¹. DMK has shown considerable α -glucosidase inhibition under cell free conditions and this inhibition might be due to the synergistic action of phenols, flavonoids and other compounds present in DMK. In addition, DMK demonstrated a significant anti-glycation activity under cell free condition. AGEs are proteins or lipids that become glycated because of long standing sugar exposures in diabetes and, contribute in the progression of diabetes associated complications. The anti-glycation activity was found to be correlated with flavonoids, phenolic acids and other phytochemicals of the DMK. The enhanced cellular glucose uptake and anti-alpha glucosidase activity of DMK provides the evidence in support of its anti-diabetic potential. Moreover, the anti-glycation activity indicates the potential of DMK in treating diabetic associated complications.

Obesity is closely associated with diabetes mellitus and characterized by excessive growth of adipose tissue mass because of hyperplasia and hypertrophy of adipocytes. Inhibition of pre-adipocytes differentiation is one of the key therapeutic strategies to inhibit adipogenesis^{3,4,5}. Our results showed that DMK significantly suppressed the adipogenic differentiation, lipid content and intracellular triglycerides in 3T3 L1 cells. A significant reduction in lipid content (80 %) and triglyceride content (43.85 %) was noted at 250 μ g/ml concentration of DMK. Adipogenesis involves the process of differentiation of pre-adipocytes into adipocytes and it tightly synchronized with the sequential activations of various

transcriptional regulators and downstream genes^{4,5}. A downregulation observed at mRNA expression of two important transcription master regulators (PPAR γ and C/EBP α) of adipogenesis indicated anti-adipogenic potential of DMK. Furthermore, we demonstrated that DMK downregulated mRNA expression of downstream adipogenic marker (LPL, AP2, and adiponectin) genes that are responsible for lipid accumulation in adipocytes. LPL plays a critical role in triglyceride uptake and storage. Adiponectin plays an important role in enhancing insulin sensitivity and increasing fatty acid oxidation in liver and muscle. In addition to adiponectin, AP2 is also an adipokines have a specific role in lipolysis¹¹⁰. Therefore, the bioactive phytochemicals in DMK might have capacity to inhibit adipocyte differentiation by down regulating transcription factors and adipogenic genes that could be an effective strategy in the treatment of obesity.

Several studies reported that medicinal property of various plants was correlated with their bioactive phytochemical compounds which have therapeutic potential against diseases^{7,105,106,107}. The herbo-mineral formulation DMK contains multiple bioactive compounds. The understanding of mode of action of these bioactive compounds on multiple targets is very important for cure and prevention of a disease. These compounds have been studied extensively with their chemical structure and mode of action. Catechin, a flavonoid present in DMK exhibit anti-hyperglycemic, anti-hyperlipidemic, anti-glycosidase and anti-AGEs activities by enhancing anti-oxidant defense system^{26, 27, 28}. Myricetin demonstrated glucoregulatory activity as a GLP-1R agonist for the treatment of T2DM²⁹. Also it suppresses differentiation of pre-adipocytes into adipocytes by down regulating transcription factor (PPAR γ , C/EBP α) and adipogenic marker genes, in addition, it enhances lipolysis by releasing glycerol from fully differentiated adipocytes³⁰. DMK contains Astragalin which is multifaceted compound regulating various molecular

482 targets such as transcription factors, enzymes, kinases etc. with diversified pharmacological
483 applications including anti-obesity and anti-diabetic properties ³¹. The flavonoid rutin has anti-
484 hyperglycemic property including decrease of carbohydrates absorption in small intestine,
485 increase of tissue glucose uptake, stimulation of insulin secretion from beta cells, protecting
486 Langerhans islet against degeneration and inhibition of tissue gluconeogenesis ³². Rutin also
487 decreases reactive oxygen species, advanced glycation end-product precursors and prevent all
488 kind of pathologies associated with diabetes ³³. DMK contain Quercetin, which is a flavonoid
489 improving insulin secretion and sensitizing activities as well as glucose utilization in peripheral
490 tissues ³⁵. It inhibits the formation of AGEs by blocking reactive dicarbonyl compounds,
491 identified as its precursors ³⁶. Also, it inhibits the adipogenesis of muscle satellite cells *in-*
492 *vitro* by suppressing the transcription of adipogenic markers ³⁷. Jung et al demonstrated that
493 apigenin significantly reduced levels of fasting blood glucose, hyper-insulinemia and HOMA-IR,
494 a surrogate marker for insulin resistance, in type I and type II diabetic animal. Moreover, it
495 significantly decreased hepatic PEPCK and G6Pase activity controlling hepatic gluconeogenesis
496 which is closely related to diabetes and obesity ³⁹. Vitexin and isovitexin are naturally occurring
497 C-glycosylated derivatives of apigenin. Both compound showed highly anti α -glucosidase
498 inhibitory activity ⁴¹. Also, two compounds inhibit the formation of AGEs significantly but failed
499 to trap reactive carbonyl species, the anti AGEs activities may be due to their free radical
500 scavenging capacity ⁴². Vitexin prevented HFD induced obesity/adipogenesis via the AMPK α
501 mediated pathway ⁴³. Kaempferol decreased TG accumulation at the dose of 25 μ M by reducing
502 the transcription factor C/EBP α in human mesenchymal stem cells (MSCs) ³⁹. Hyperoside
503 significantly inhibited receptor for anti-glycation end product (RAGE) expression and promoted
504 proliferation in AGE-stimulated ECV304 cells ⁴⁵. Daidzein stimulated glucose uptake in L6 by

505 AMPK phosphorylation increasing GLUT4 translocation to PM of muscle cells and significantly
506 suppressed the rises in blood glucose levels in db/db and KK-Ay mice ⁴⁶. Also it induced
507 survival of pancreatic β -cells and insulin secretion in type1 diabetic animal model ⁴⁷. Luteolin
508 exerted anti-adipogenic effects by down regulating adipogenic transcription factors, suppressed
509 of NF- κ B and MAPKs activation, and also improved insulin sensitivity in 3T3 L1 adipocytes,
510 suggesting that luteolin prevents obesity, associated inflammation and insulin resistance ^{49, 50}.
511 Vicenin 2 significantly exhibited anti-diabetic activity by inhibition of α -glucosidase and protein
512 tyrosine phosphatase 1B (PTP1B). It also inhibited AGEs formation by attenuating the formation
513 of protein carbonyl groups as well as modification of protein thiol groups ⁵⁶. Baicalein play a
514 novel anti-diabetic action by directly improving β -cell and human islet viability and insulin
515 secretion ⁵⁷. It decreased the intracellular lipid accumulation by down-regulation of glucose
516 uptake via repression of Akt-C/EBP α -GLUT4 signaling ⁵⁸. Chlorogenic acid reduces islet cell
517 apoptosis and improves pancreatic function ⁶⁴, also it improves glucose and lipid metabolism, via
518 AMPK activation ⁶⁵. It lowered the levels of fasting plasma glucose and HbA1c during late
519 diabetes in db/db mice ⁶⁶. Apocynin has the potential to improve insulin sensitivity ⁶⁸.
520 Ferulic acid improved insulin sensitivity and hepatic glycogenesis but inhibits gluconeogenesis
521 to maintain normal glucose homeostasis in type 2 diabetic rat ⁶⁹. Also, it has a potential to
522 modulate adipogenesis via expressing of heme oxygenase-1 (HO-1) and suppressing C/EBP α
523 and PPAR γ , triglyceride-synthesizing enzymes, fatty acid synthase (FASN) and acetyl-CoA
524 carboxylase (ACC) ⁷⁰. Caffeic acid esters are able to stimulate glucose transport in skeletal
525 muscle via increasing GLUT4 translocation, reduce hepatocellular glucose production and
526 adipogenesis in an AMPK-dependent manner ⁷¹. Ellagic acid lowered significantly blood glucose
527 level by stimulating insulin secretion ⁷³. Gallic acid and its derivatives play significant role

through activation of the AMPK/Sirt/PGC1 α pathway⁷⁴. Furthermore, it exhibited a strong protective effect on disease progression in streptozotocin (STZ) injected type 1 and 2 diabetic models. Therefore, Gallic acid has a potential therapeutic intervention in the protection and/or improvement of metabolic syndromes^{75,76,78,79}. Stearidonic acid inhibited adipocyte differentiation and reduce lipid accumulation in 3T3 L1 adipocytes through down-regulation of adipogenic transcription factors and adipogenic genes⁹⁴. Withaferin A is a leptin sensitizer; its treatment showed 20–25% reduction of body weight of diet-induced obese mice and also decreased obesity-associated abnormalities including hepatic steatosis. Withaferin A also affects the body weight of *ob/ob* and *db/db* mice which are deficient in leptin signaling suggesting that it has leptin independent effects on glucose homeostasis⁹⁷. Diosgenin a steroid saponin showed hypo-glycaemic effect and improved dyslipidemia by decreasing the hepatic lipid content in type-II diabetic model¹⁰³. The synergistic effect of phyto-constituents present in polyherbal formulation always acts on multiple target and pathways of disease, which is not available in single herb formulation^{8, 132}. Moreover, polyherbal formulation contains very minimum amount of compound exert very little or no side effect compared to single herb formulation. The enhanced effectiveness of the DMK as anti diabetic and anti adipogenic agent might be through additive or synergistic actions of its multiple bioactive compounds.

We concluded that the DMK is capable of enhancing glucose uptake in cells, lowering blood sugar level, anti- α glucosidase activity, anti-glycation activity and anti-adipogenic property indicating its potential in treating diabetic and its associated complication. All the activities of DMK could be due to the synergistic effect of bioactive compounds. Moreover, no side effect is expected as the formulation is fully nature derived and has long term historical use. The observed multi targets mode of action of DMK puts it in a rather different class of

therapeutic agents; and offers a new preventive and therapeutic option in holistic DM management.

Acknowledgments

We are thankful to Patanjali Research Foundation Trust, Haridwar, India for financial support. We thank Mr. Sunil Kumar and Pratima Kumari for their valuable help with culturing cells and extracts preparation. We are also thankful to Mr. Lalit Mohan, Mr. Tarun Ji, and Mr. Gagan Ji for their administrative support.

Author Contributions

Conceptualization and experimental design: SKD, AJ, VS, CSJ, AB. Performed the experiments: SKD, AJ, LB, KJ, VKS, NS, SV Analyzed the data: SKD, AJ, SS, VS, CSJ, Manuscript writing: AJ, SKD, VS, SS, Manuscript reviewed: SKD, AJ, VS, CSJ, VKS. All authors read and approved the final version of the manuscript.

Competing Interests

The authors declare no competing interests.

References

1. Cho, N.H et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract.***138**, 271-281, (2018).
2. Martyn, J.A., Kaneki, M., Yasuhara, S. Obesity-induced insulin resistance and hyperglycemia: etiologic factors and molecular mechanisms. *Anesthesiology.* **109**, 137-48, (2008).
3. Lowe, C.E., O'Rahilly, S., Rochford, J.J. Adipogenesis at a glance. *J Cell Sci.* **124**, 2681-2686, (2011).
4. Li, K.K. et al. Cocoa tea (*Camellia ptilophylla*) water extract inhibits adipocyte differentiation in mouse 3T3-L1 pre-adipocytes. *Sci Rep.* **6**, 20172, (2016).

- 580 **5.** Ji, S., Doumit, M.E., Hill, R.A. Regulation of Adipogenesis and Key Adipogenic Gene
581 Expression by 1, 25-Dihydroxyvitamin D in 3T3-L1 Cells. PLoS One. **10**, e0126142. (2015).
- 582 **6.** Subramani, P., Gan, S. T., Sokkalingam A. D. Polyherbal formulation: Concept of ayurveda,
583 Pharmacogn Rev. **8**, 73–80, (2014).
- 584 **7.** Yuan, H., Ma, Q., Cui, H., Liu, G., Zhao, X., Li, W., Piao, G. How Can Synergism of
585 Traditional Medicines Benefit from Network Pharmacology? Molecules. **22**, 1135, (2017).
- 586 **8.** Grover, J.K., Yadav, S., Vats, V. Medicinal plants of India with anti-diabetic potential. J
587 Ethanopharmacol. **81**, 81-100, (2002).
- 588 **9.** Leung, L., Birtwhistle, R., Kotecha, J., Hannah, S., Cuthbertson, S. Anti-diabetic and
589 hypoglycaemic effects of *Momordica charantia* (bitter melon): a mini review. Br J Nutr. **102**,
590 1703-1708, (2009).
- 591 **10.** Husain, G.M., Singh, P.N., Kumar, V. Antidiabetic activity of standardized extract of
592 *Picrorhiza kurroa* in rat model Drug Discov Ther. **3**, 88-92, (2009).
- 593 **11.** Kumar, V., Van, S. J. A Review of *Swertia chirayita* (Gentianaceae) as a Traditional
594 Medicinal Plant. Front. Pharmacol. **6**, 308. (2016).
- 595 **12.** Khosla, P., Bhanwra, S., Singh, J., Seth, S., Srivastava, R.K. A study of hypoglycaemic
596 effects of *Azadirachta indica* (Neem) in normal and alloxan diabetic rabbits. Indian J Physiol
597 Pharmacol. **4**, 69-74, (2000).
- 598 **13.** Kumar, P., Kale, R. K., Baquer N.Z. Antihyperglycemic and protective effects of *Trigonella*
599 foenum graecum seed powder on biochemical alterations in alloxan diabetic rats. Eur Rev
600 Med Pharmacol Sci. **16**, 18-27, (2012).

14. Raza, A., Butt, M.AS., Ul-Haq, I., Ansar, H., Suleria, R. Jamun (*Syzygium cumini*) seed and fruit extract attenuate hyperglycemia in diabetic rats. Asian Pacific Journal of Tropical Biomedicine. **7**, 750-754. (2017).
15. Udayakumar, R. et al. Hypoglycaemic and Hypolipidaemic Effects of *Withania somnifera* Root and Leaf Extracts on Alloxan-Induced Diabetic Rats. Int J Mol Sci.**10**, 2367-2382, (2009).
16. Subash, A.K., Augustine, A. Hypolipidemic effect of methanol fraction of *Aconitum heterophyllum* wall ex Royle and the mechanism of action in diet-induced obese rats. J Adv Pharm Technol Res. **3**, 224-228, (2012).
17. Carrasco, G. C., Guzman, L., Maccioni, R.B., Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimers Dis. **2012**, 674142, (2012).
18. Agarwal, S.P., Karmarkar, R., Anwer, M.K., Khar, R.K. Shilajit: A Review. Phytother. Res. **21**, 401-405, (2007).
19. Ip, S.P. et al. Quality assurance for Chinese herbal formulae: standardization of IBS-20, a 20-herb preparation. Chin Med. **5**, 8, (2010).
20. Lin, D. et al An overview of plant phenolic compounds and their importance in human nutrition and management of Type 2 Diabetes. Molecules. **21**, E1374. (2016).
21. Dembinska, K. A., Mykkanen, O., Kiec, W. B., Mykkanen, H. Antioxidant phytochemicals against type2 diabetes. Br J Nutr. **99**, ES109-17, (2008).
22. Singh, P. et al. Potential dual role of eugenol in inhibiting advanced glycation end products in diabetes: proteomic and mechanistic insights. Sci Rep. **6**, 18798, (2016).
23. Nair, A.B., Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. **7**, 27-31, (2016).

24. Amrani, F. E., Rhallab, A., Alaoui, T., Badaoui, K. E., Chakir, S. Hypoglycaemic effect of Thymelaea hirsuta in normal and streptozotocin-induced diabetic rats. J Med Plants Res. **3**, 625-629, (2009).
25. Etuk, E.U. Animals models for studying diabetes mellitus. Agric biol J N Am. **1**, 130-134, (2010).
26. Samarghandian, S., Nezhad, M.A., Farkhondeh, T. Catechin Treatment Ameliorates Diabetes and Its Complications in Streptozotocin-Induced Diabetic Rats. Dose Response. **6**,15. (2017).
27. Wu, Q. et al. A Significant Inhibitory Effect on Advanced Glycation End Product Formation by Catechin as the Major Metabolite of Lotus Seedpod Oligomeric Procyanidins. Nutrients. **6**, 3230-3244, (2014).
28. Suzuki, T., Pervin, M., Goto, S., Isemura, M., Nakamura, Y. Beneficial Effects of Tea and the Green Tea Catechin Epigallocatechin-3-gallate on Obesity. Molecules. **29**, 21, E1305, (2016).
29. Li, Y. et al M. Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist. FASEB J, **31**, 2603-2611, (2017).
30. Wang, Q., Wang, S., Yang, X., You, P., Zhang, W. Myricetin suppresses differentiation of 3 T3-L1 preadipocytes and enhances lipolysis in adipocytes. Nutr Res. **35**, 317-27, (2015).
31. Riaz,A. et al. Astragalin: A Bioactive Phytochemical with Potential TherapeuticActivities. Advances in Pharmacological Sciences. **32**, 1-15, (2018).
32. Ghorbani, A. Mechanisms of antidiabetic effects of flavonoid rutin. Biomed Pharmacother. **96**, 305-312, (2017).
33. Ganeshpurkarb, A., Bansalc,D., Dubey, N. Glycolytic enzyme inhibitory and antiglycation potential of rutin. Future Journal of Pharmaceutical Sciences. **3**, 158-162, (2017).

34. Choi, I., Park, Y., Choi, H., Lee, E.H. Anti-adipogenic activity of rutin in 3T3-L1 cells and mice fed with high-fat diet. *Biofactors*, **26**, 273-281, (2006).
35. Eid, H.M., Haddad, P.S. The Antidiabetic Potential of Quercetin: Underlying Mechanisms. *Curr Med Chem*. **24**, 355-364, (2017).
36. Li, X., Zheng, T., Sang, S., Lv, L. Quercetin inhibits advanced glycation end product formation by trapping methylglyoxal and glyoxal. *J Agric Food Chem*. **17**, 12152-12158, (2014).
37. Funakoshi, T. et al. Quercetin inhibits adipogenesis of muscle progenitor cells *in vitro*. *Biochem Biophys Rep*. **21**, 39-44. (2017).
38. Choi, J.S. et al. C-glycosylation on anti-diabetic, anti-Alzheimer's disease and anti-inflammatory potential of apigenin. *Food Chem Toxicol*. **64**, 27-33. (2014).
39. Jung, U.J., Cho, Y.Y., Choi, M.S. Apigenin Ameliorates Dyslipidemia, Hepatic Steatosis and Insulin Resistance by Modulating Metabolic and Transcriptional Profiles in the Liver of High-Fat Diet-Induced Obese Mice. *Nutrients*. **8**, 305. (2016).
40. Gómez, Z.S. et al. Phenolic compounds apigenin, hesperidin and kaempferol reduce *in vitro* lipid accumulation in human adipocytes. *J Transl Med*. **15**, 237, (2017).
41. Yao, Y., Cheng, X., Wang, L., Wang, S., Ren, G. Determination of Potential α -Glucosidase Inhibitors from Azuki Beans (*Vigna angularis*). *Int J Mol Sci*. **12**, 6445-6451, (2011).
42. Peng, X. et al. M. Inhibitory effect of mung bean extract and its constituents vitexin and isovitexin on the formation of advanced glycation endproducts. *Food Chem*. **106**, 475-481, (2008).
43. Peng, Y. et al. Vitexin ameliorates high fat diet-induced obesity in male C57BL/6J mice via the AMPK α -mediated pathway. *Food Funct*. **10**, 1940-1947, (2019).

- 670 **44.** Zhang, Y., Wang, M., Dong, H., Yu, X., Zhang, J. Anti-hypoglycemic and hepatocyte-
671 protective effects of hyperoside from *Zanthoxylum bungeanum* leaves in mice with high-
672 carbohydrate/high-fat diet and alloxan-induced diabetes. *Int J Mol Med.* **41**, 77-86, (2018).
- 673 **45.** Zhang, Z., Sethiel, M.S., Shen, W., Liao, S., Zou, Y. Hyperoside downregulates the receptor
674 for advanced glycation end products (RAGE) and promotes proliferation in ECV304 cells via
675 the c-Jun N-terminal kinases (JNK) pathway following stimulation by advanced glycation
676 end-products in vitro. *Int J Mol Sci.* **18**, 22697-707. (2013).
- 677 **46.** Cheong, S.H. et al. Daidzein promotes glucose uptake through glucose transporter 4
678 translocation to plasma membrane in L6 myocytes and improves glucose homeostasis in
679 Type 2 diabetic model mice. *The Journal of Nutritional Biochemistry.* **25**, 136-143, (2014).
- 680 **47.** Sun, M. et al. Zhang, H. Daidzein: A review of pharmacological effects. *Afr J Tradit*
681 *Complement Altern Med.* **13**, 117-132, (2016).
- 682 **48.** Kim, M.H. et al. Genistein and daidzein repress adipogenic differentiation of human adipose
683 tissue-derived mesenchymal stem cells via Wnt/ β -catenin signalling or lipolysis. *Cell Prolif.*
684 **43**, 594-605, (2010).
- 685 **49.** Nepali, S. et al. Luteolin is a bioflavonoid that attenuates adipocyte-derived inflammatory
686 responses via suppression of nuclear factor- κ B/mitogen-activated protein kinases pathway.
687 *Pharmacogn Mag.* **11**, 627–635. (2015).
- 688 **50.** Park, H.S. et al. Luteolin inhibits adipogenic differentiation by regulating PPARgamma
689 activation. *Biofactors.* **35**, 373-379, (2009).
- 690 **51.** Habtemariam, S. A-glucosidase inhibitory activity of kaempferol-3-O-rutinoside. *Nat Prod*
691 *Commun.* **6**, 201-203, (2011).

- 692 **52.** Lal, S.S. et al. Synthesis and antiglycation activity of kaempferol-3-O-rutinoside
693 (nicotiflorin). *Med Chem.* **8**, 415-420, (2012).
- 694 **53.** Jang, S.J. et al. Screening of Korean Natural Products for Anti-Adipogenesis Properties and
695 Isolation of Kaempferol-3-O-rutinoside as a Potent Anti-Adipogenetic Compound
696 from *Solidago virgaurea*. *Molecules.* **21**, 226. (2016).
- 697 **54.** Hartogh, D.J.D., Tsiani, E. Antidiabetic Properties of Naringenin: A Citrus Fruit Polyphenol,
698 *Biomolecules.*, **9**, 99. (2019).
- 699 **55.** Richard, A.J., Vaughan, Z.A., Ribnicky, D.M., Stephens, J.M. Naringenin Inhibits
700 Adipogenesis and Reduces Insulin Sensitivity and Adiponectin Expression in Adipocytes.
701 *Evid Based Complement Alternat Med.* 549750, (2013).
- 702 **56.** Islam, M.N., Ishita, I.J., Jung, H.A., Choi, J.S. Vicenin 2 isolated from *Artemisia capillaris*
703 exhibited potent anti-glycation properties. *Food Chem Toxicol.* **69**, 55-62, (2014).
- 704 **57.** Fu, Y. et al. Baicalein Protects against Type 2 Diabetes via Promoting Islet β -Cell Function
705 in Obese Diabetic Mice *Int J Endocrinol.* 846742, (2014).
- 706 **58.** Nakao, Y., Yoshihara, H., Fujimori, K. Suppression of Very Early Stage of Adipogenesis by
707 Baicalein, a Plant-Derived Flavonoid through Reduced Akt-C/EBP α - GLUT4 Signaling-
708 Mediated Glucose Uptake in 3T3-L1 Adipocytes. *PLoS One.* **11**, e0163640, (2016).
- 709 **59.** Xu, Y. et al. Calycosin protects HUVECs from advanced glycation end products-induced
710 macrophage infiltration. *J Ethnopharmacol.* **137**, 359-70. (2011).
- 711 **60.** Nandini, H.S., Naik, P.R. Action of corilagin on hyperglycemia, hyperlipidemia and
712 oxidative stress in streptozotocin-induced diabetic rats. *Chem Biol Interact.* **299**, 186-193,
713 (2019).

61. Apontes, P. et al. Mangiferin stimulates carbohydrate oxidation and protects against metabolic disorders induced by high-fat diets. *Diabetes*. **63**, 3626-3636. (2014).
62. Hou, J. et al. Mangiferin suppressed advanced glycation end products (AGEs) through NF- κ B deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet-diabetic cardiomyopathy rats. *Can J Physiol Pharmacol*. **94**, 332-340. (2016).
63. Subash-babu. P., Alshatwi, A. A. Evaluation of Antiobesity Effect of Mangiferin in Adipogenesis-Induced Human Mesenchymal Stem Cells by Assessing Adipogenic Genes. *Journal of Food Biochemistry*. **39**, 28-38. (2015).
64. Yin, X. L. Xu, B.Q. Zhang, Y.Q. *Gynura divaricata* rich in 3, 5-/4, 5-dicaffeoylquinic acid and chlorogenic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice. *Nutr Metab*. **15**, 73, (2018).
65. Ong, K.W. Hsu, A. Tan, B.K. Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by AMPK activation. *Biochem Pharmacol*. **85**, 1341-1351. (2013).
66. Jin, S. et al. Chlorogenic Acid Improves Late Diabetes through Adiponectin Receptor Signaling Pathways in *db/db* Mice. *PLoS One*, **10**, e0120842. (2015).
67. Chang, W.C. et al. Scopoletin protects against methylglyoxal-induced hyperglycemia and insulin resistance mediated by suppression of advanced glycation endproducts (AGEs) generation and anti-glycation. *Molecules*, **20**, 2786-801, (2015).
68. Meng,R., Zhu, D.L., Bi, Y., Yang,H.D., Wang, Y.P. Apocynin Improves Insulin Resistance through Suppressing Inflammation in High-Fat Diet-Induced Obese Mice, Mediators of Inflammation. 858735, (2010).

69. Narasimhan, A., Chinnaiyan, M., Karundevi, B. Ferulic acid exerts its antidiabetic effect by modulating insulin-signalling molecules in the liver of high-fat diet and fructose-induced type-2 diabetic adult male rat. *Appl Physiol Nutr Metab.* **40**, 769-781, (2015).
70. Koh, E.J., Kim, K.J., Seo, Y.J., Choi, J., Lee, B.Y. Modulation of HO-1 by Ferulic Acid Attenuates Adipocyte Differentiation in 3T3-L1 Cells. *Molecules*, **22**, E745. (2017).
71. Eid,H.M.,Thong,F., Nachar,A., Haddad,P.S.Caffeic acid methyl and ethyl esters exert potential antidiabetic effects on glucose and lipid metabolism in cultured murine insulin-sensitive cells through mechanisms implicating activation of AMPK. *Pharm Biol.* **55**, 2026-2034, (2017).
72. Jung, U.J., Lee, M.K., Park, Y.B., Jeon, S.M., Choi, M.S. Antihyperglycemic and antioxidant properties of caffeic acid in db/db mice. *J Pharmacol Exp Ther.* **318**, 476-483. (2006).
73. Fatima, N. et al. Ellagic acid in *Embllica officinalis* exerts antidiabetic activity through the action on β cells of pancreas. *Eur J Nutr.* **56**, 591-601, (2017).
74. Doan, K.V.et al. Gallic Acid Regulates Body Weight and Glucose Homeostasis Through AMPK Activation. *Endocrinology*.**156**, 157-168, (2015).
75. Adefegha, S.A, Oboh, G., Ejakpovi, I.I., Oyeleye, S.I. Antioxidant and antidiabetic effects of gallic and protocatechuic acids: a structure-function perspective. *Comparative Clinical Pathology.* **24**, 1579–1585, (2015).

- 753 **76.** Oboh, G., Ogunsuyi, O.B., Ogunbadejo, M.D., Adefegha, S.A. Influence of gallic acid on a-
754 amylase and a-glucosidase inhibitory properties of acarbose. *J Food Drug Anal.* **24**, 627-634,
755 (2016).
- 756 **77.** Umadevi, S., Gopi, V., Vellaichamy, E. Inhibitory effect of gallic acid on advanced glycation
757 end products induced up-regulation of inflammatory cytokines and matrix proteins in H9C2
758 (2-1) cells. *Cardiovasc Toxicol.***13**,396-405, (2013).
- 759 **78.** Aranaz, P,et al. Phenolic Compounds Inhibit 3T3-L1 Adipogenesis Depending on the Stage
760 of Differentiation and Their Binding Affinity to PPAR γ . *Molecules.* **24**, E1045, (2019).
- 761 **79.** Bak, E.J. et al. Gallic acid improves glucose tolerance and triglyceride concentration in diet-
762 induced obesity mice. *Scand J Clin Lab Invest.***73**, 607-614, (2013).
- 763 **80.** Chang, W.C. et al. Protective Effect of Vanillic Acid against Hyperinsulinemia,
764 Hyperglycemia and Hyperlipidemia via Alleviating Hepatic Insulin Resistance and
765 Inflammation in High-Fat Diet (HFD)-Fed Rats. *Nutrients.* **7**, 9946–9959, (2015).
- 766 **81.** van-Loon, L.J. et al. Amino acid ingestion strongly enhances insulin secretion in patients
767 with long-term type 2 diabetes. *Diabetes Care.* **26**, 625-630, (2003).
- 768 **82.** Natarajan, S, K. et al. Effect of oral supplementation of free amino acids in type 2 diabetic
769 patients- a pilot clinical trial. *Med Sci Monit.* **8**, 131-137, (2002).
- 770 **83.** Yoshinari, O., Igarashi, K. Anti-Diabetic Effect of Trigonelline and Nicotinic Acid, on KK-
771 Ay Mice, *Curr Med Chem.* **17**, 2196-2202, (2010).
- 772 **84.** Valdés-Ramos, R., Guadarrama-López, A.L., Martínez-Carrillo, B.E., Benítez-Arciniega,
773 A.D. Vitamins and Type 2 Diabetes Mellitus, *Endocr Metab Immune Disord Drug Targets.*,
774 **15**, 54-63, (2015).

- 775 **85.** Kim, B., Choi, K.M., Yim, H.S., Lee, M.G. Ascorbic acid enhances adipogenesis of 3T3-L1
776 murine preadipocyte through differential expression of collagens. *Lipids Health Dis.* **12**, 182,
777 (2013).
- 778 **86.** Dakhale, G.N., Chaudhari, H.V., Shrivastava, M. Supplementation of Vitamin C Reduces
779 Blood Glucose and Improves Glycosylated Hemoglobin in Type 2 Diabetes Mellitus: A
780 Randomized, Double-Blind Study. *Adv Pharmacol Sci*, **2011**, 195271, (2011).
- 781 **87.** Nagai, R., Nagai, M., Shimasaki, S., Baynes, J.W., Fujiwara, Y. Citric acid inhibits
782 development of cataracts, proteinuria and ketosis in streptozotocin (type1) diabetic rats.
783 *Biochem Biophys Res Commun.* **393**, 118-122, (2010).
- 784 **88.** Muroyama, K. et al. Anti-obesity effects of a mixture of thiamin, arginine, caffeine, and citric
785 acid in non-insulin dependent diabetic KK mice. *J Nutr Sci Vitaminol.* **49**, 56-63, (2003).
- 786 **89.** Trivedi, N. A. Mazumdar, B. Bhatt, J. D. Hemavathi, K. G. Effect of shilajit on blood
787 glucose and lipid profile in alloxan- Effect of shilajit on blood glucose and lipid profile in
788 alloxaninduced diabetic rats induced diabetic rats. *Indian Journal of pharmacology*, **36**, 373-
789 376, (2004).
- 790 **90.** Hafizur, R.M. et al. Cinnamic acid exerts anti-diabetic activity by improving glucose
791 tolerance in vivo and by stimulating insulin secretion in vitro. *Phytomedicine.* **22**, 297-300.
792 (2015).
- 793 **91.** Mnafigui, K. et al. Anti-obesity and cardioprotective effects of cinnamic acid in high fat diet-
794 induced obese rats. *J Food Sci Technol.* **52**, 4369-77, (2015).
- 795 **92.** Jovanovski, E, et al. The effect of alpha-linolenic acid on glycemic control in individuals
796 with type 2 diabetes-A systematic review and meta-analysis of randomized controlled
797 clinical trials. *Medicine*, **96**, e6531, (2017).

- 798 **93.** Prasanna, G., Saraswathi, N.T. Linolenic acid prevents early and advanced glycation end-
799 products (AGEs) modification of albumin. *Int J Biol Macromol.* **95**, 121-125, (2017).
800
- 801 **94.** Li, Y. et al. Huggins, K.W. Suppression of adipocyte differentiation and lipid accumulation
802 by stearidonic acid (SDA) in 3T3 L1 cells, *Lipids Health Dis.* **16**, 181. (2017).
803
- 804 **95.** Kavanagh, K., Flynn, D.M., Jenkins, K.A., Wilson, M.D., Chilton, F.H. Stearidonic and γ -
805 linolenic acids in echium oil improves glucose disposal in insulin resistant monkeys.
806 *Prostaglandins Leukot Essent Fatty Acids.* **89**, 39-45, (2013).
- 807 **96.** Aruna, P., Venkataramanamma, D., Singh, A.K. Singh, R.P. Health Benefits of Punicic Acid:
808 A Review. *Food Science and Food Safety.* **15**, 16-27, (2016).
- 809 **97.** Lee, J. et al. Withaferin A is a Leptin Sensitizer with Strong Anti-Diabetic Properties in
810 Mice. *Nat Med.* **22**, 1023–1032,(2016).
- 811 **98.** Khalilpourfarshbafi, M., Devi-Murugan, D., Abdul-Sattar, M.Z., Sucedaram, Y. Abdullah,
812 N.A. Withaferin A inhibits adipogenesis in 3T3- F442A cell line, improves insulin sensitivity
813 and promotes weight loss in high fat dietinduced obese mice. *PLoS One.* **14**,
814 e0218792, (2019).
- 815 **99.** Tekula, S., Khurana, A., Anchi, P., Godugu, C. Withaferin-A attenuates multiple low doses
816 of Streptozotocin (MLD-STZ) induced type 1 diabetes. *Biomed Pharmacother.* **106**, 1428-
817 1440, (2018).
- 818 **100.** Gorelick, J., Rosenberg, R., Smotrich, A., Hanuš, L. Bernstein, N. Hypoglycemic activity
819 of withanolides and elicited *Withania somnifera*. *Phytochemistry.* **116**, 283-289, (2015).
- 820 **101.** Saxena, A.M., Bajpai, M.B., Murthy, P.S., Mukherjee, S.K. Mechanism of blood sugar
lowering by a swerchirin-containing hexane fraction (SWI) of *Swertia chirayita*. *Indian J Exp*
Biol. **31**, 178-181, (1993).

- 821 **102.** Wang, T. et al. Trillin, a steroidal saponin isolated from the rhizomes of *Dioscorea*
822 *nipponica*, exerts protective effects against hyperlipidemia and oxidative stress. *J*
823 *Ethnopharmacol.* **139**, 214-20, (2012).
- 824 **103.** Naidu, P.B. et al. Diosgenin reorganizes hyperglycaemia and distorted tissue lipid profile
825 in high fat diet-streptozotocin induced diabetic rats, *J Sci Food Agric.* **95**, 3177-3182. (2015).
- 826 **104.** Uemura, T. et al. Diosgenin, the main aglycon of fenugreek, inhibits LXR α activity in
827 HepG2 cells and decreases plasma and hepatic triglycerides in obese diabetic mice. *J*
828 *Nutr.* **141**, 17-23, (2011).
- 829 **105.** Gopalakrishna Pillai, G.K. et al. Antidiabetic potential of polyherbal formulation
830 DB14201: Preclinical development, safety and efficacy studies. *J Ethnopharmacol.* **197**, 218-
831 230, (2017).
- 832 **106.** Yadav, D. et al. In vitro toxicity and antidiabetic activity of a newly developed
833 polyherbal formulation (MAC-ST/001) in streptozotocin-induced diabetic Wistar rats.
834 *Protoplasma.* **250**, 741-749, (2013).
- 835 **107.** Mutalik, S., Chetana, M., Sulochana, B., Devi, P.U., Udupa, N. Effect of Dianex, a herbal
836 formulation on experimentally induced diabetes mellitus. *Phytother Res.* **19**, 409-415, (2005).
- 837 **108.** Chawla, R. et al. Evidence based herbal drug standardization approach in coping with
838 challenges of holistic management of diabetes: a dreadful lifestyle disorder of 21st century. *J*
839 *Diabetes Metab Disord.* **12**, 35, (2013).
- 840 **109.** De Fronzo, R.A., Tripathy, D. Skeletal muscle insulin resistance is the primary defect in
841 type 2 diabetes. *Diabetes Care.* **32**, S157-163, (2009).
- 842 **110.** Ertunc, M.E. et al. Secretion of fatty acid binding protein AP2 from adipocytes through a
843 nonclassical pathway in response to adipocyte lipase activity. *J Lipid Res.* **56**, 423-434, 2015.

844 **111.** Saxena, M., Saxena, J., Nema, R., Singh, D, Gupta A. Phytochemistry of Medicinal
845 plants. J Pharmacogn Phytochem. **1**,168-182, (2013)
846
847

Fig 2. HPLC Profiling of the Major Constituents of Divya MadhuKalp (DMK). The HPLC chromatogram of the components was monitored at 230 nm. Here, the peaks showed for standard used in HPLC analysis are Gallic acid, Vanillic Acid, Caffeic Acid, Trigonelline, Adenosine, Rutin, Quercetin, Picroside I, Picroside II, Trans-cinnamic acid, Apigenin.

Fig 3. Effect of Divya MadhuKalp (DMK) and its Constituents on Cell Viability. The effects of DMK and its nine ingredients (*Mc*, *Pk*, *Sc*, *Ai*, *Tf*, *Syc*, *Ws*, *Ah*, and *Sh*) were studied for cell viability in mouse 3T3 L1 pre-adipocytes. Cell viability was determined by MTT after 24 h of treatment and extracts concentration ranged from 0-1500 µg/ml. Data represented the Mean ± SEM (n ≥ 3).

Fig 4. Effect of Divya MadhuKalp (DMK) and its Ingredients on Glucose Uptake in Rat Skeletal Muscle (L6) Cells. Cells were treated with extracts in presence of insulin for 24 h. Metformin (MTF– 100 µM) was used as a positive control. Glucose Uptake (2-NBDG 100 µg/ml) was quantified by Flow Cytometry of 8000 cells. (A) Effect of different doses of DMK (0-250 µg/ml) and (B) single dose (62.5 µg/ml) of its ingredients (*Mc*, *Pk*, *Sc*, *Ai*, *Tf*, *Syc*, *Sc*, *Wi*, *Ws*, *Ah*, and *Sh*) on glucose uptake. (C) Fluorescence intensity change (2-NBDG uptake) was observed in 3T3–L1 cells incubated with DMK and its ingredients (62.5 µg/ml). These data were harvested to compute the fold changes shown in (B). DMSO was used as a Vehicle control (Vc). All the data are expressed as Means ± SEM of three independent experiments. * $p < 0.05$ or ** $p < 0.01$ as compared to vehicle control.

Fig 5. Effect of Divya MadhuKalp (DMK) on α -Glucosidase and Anti Glycation Activity.
(A) Inhibitory potency of DMK against α -glucosidase activity. Acarbose is taken as the reference standard. (B) Effect on DMK Advanced Glycation End products (AGEs) of BSA up to 4 weeks of incubation. Aminoguanidine (AG) was used as the reference standard. The results were obtained from three independent experiments and expressed as Mean $\pm$ SEM.

Fig 6. In-Vivo Efficacy of Divya MadhuKalp (DMK). (A) Effect of vehicle control (Vc), Glibenclamide (GLB; 10 mg/kg) and DMK (200 mg/kg) on blood glucose level in normal rats. (B) Effect of vehicle control (Vc), Glibenclamide (GLB; 10 mg/kg) and DMK (200 mg/kg) on blood glucose level of OGTT in normal rats. Values in the results are expressed as mean $\pm$ SEM, (n=8), # denotes significantly difference (p<0.05) in 0 min and 30 min time points (Student's t-test); *p<0.05, **p<0.01 significantly different in comparison to control at respective time points (ANOVA followed by Dunnett's t-test).

Fig 7. Anti-adipogenic Effect of Divya MadhuKalp (DMK) and its Ingredients in Mouse 3T3 L1 Pre-adipocytes. Lipids were stained with Oil Red O (MDI: adipogenic differentiation media) and quantified at 492 nm. (A) Representative photomicrographs at 20X showed lipid accumulation in the cells and, (B) Relative lipid content of DMK (0-250 µg/ml) treated cells. (C) Microscopic images (20X) of Oil red O stained adipocytes treated with DMK ingredients (*Mc*, *Pk*, *Sc*, *Ai*, *Tf*, *Syc*, *Ws*, *Ah*, and *Sh*) (D) Relative lipid content of DMK ingredients. The dose used for each ingredient was 250 µg/ml except for *Tf* (62.5 µg/ml) based on MTT assay. (E) Effect of DMK on the triglyceride deposition in differentiated 3T3–L1 cells. Cells were cultured in adipogenic differentiation media with

909 or without treatment of DMK and, triglyceride content was quantified at 540 nm. DMSO
910 was used as a Vehicle control (Vc). Uninduced (UI) cells were not treated with MDI. All the
911 data were expressed as means $\pm$ SEM of three independent experiments. UI: Uninduced. *p
912 < 0.05 or **p< 0.01 as compared to Vehicle control (Vc).
913
914

Fig 8. Effect of Divya MadhuKalp (DMK) on the Expression of Adipogenic Transcription Factor and Target Gene Markers. The 3T3 L1 mouse pre-adipocytes were induced to differentiate into adipocytes in MDI (adipogenic differentiation media) medium with (62.5, 125 and 250 µg/ml) or without DMK. Uninduced (UI) cells were not treated with MDI. mRNA was extracted and the expression of adipogenic transcription factors and related adipogenic modulators genes were detected using one step RT-PCR. The relative expression level of (A) PPARγ, (B) C/EBPα, (C) LPL, (D) AP2, and (E) Adiponectin are presented as the fold change in DMK treated groups vs. untreated after normalization to GAPDH mRNA levels. Values are expressed as the mean ± SEM. *p < 0.05 or **p < 0.01 as compared to control (Untreated).

930 **Table 1. Composition of Divya MadhuKalp (DMK)**

Name of the Herb	Parts used	Quantity (%)
<i>Momordica charantia</i> (Mc)	Fruit	14.06
<i>Picrorrhiza kurrora</i> (Pk)	Rhizome	14.06
<i>Swertia chirata</i> (Sc)	Whole plant	14.06
<i>Azadirachta indica</i> (Ai)	Fruit	14.06
<i>Trigonella foenum-graecum</i> (Tf)	Seed	14.06
<i>Syzygium cumini</i> (Syc)	Seed	14.06
<i>Withania somnifera</i> (Ws)	Root	7.04
<i>Aconitum heterophyllum</i> (Ah)	Tuber	7.04
<i>Shilajeet</i> (Asphaltum) (Sh)	Water Extract	1.56

931

932 **Table 2. Phytochemical category and therapeutic effects of referenced bioactive compounds**
 933 **present in Divya MadhuKalp (DMK)**

Compound name	Category	Therapeutic effects with reference
Catechin	Flavan-3-ol	Anti-diabetic ²⁶ , Anti- glycation ²⁷ , anti-obesity effects ²⁸
Myricetin	Flavonoid	Anti-diabetic ²⁹ , Anti-adipogenic ³⁰
Astragalin	Flavonoid	Anti-diabetic, Anti-adipogenic ³¹
Rutin	Flavonoid	Anti-diabetic ³² , Anti- glycation ³³ , Anti-adipogenic ³⁴
Quercetin	Flavonoid	Anti-diabetic ³⁵ , Anti- AGEs ³⁶ , Anti-adipogenic ³⁷
Apigenin	Flavones	Anti-diabetic ³⁸ , anti-obesity effects ^{39, 40}
Vitexin	Flavone glycoside	Anti-diabetic ³⁸ , Anti- α -glucosidase ⁴¹ , Anti- glycation ⁴² , Anti-adipogenic ⁴³
Isovitexin	Flavone	Anti-diabetic ³⁸ , Anti- α -glucosidase ⁴¹ , Anti- glycation ⁴²
Hyperoside	Flavonoid	Anti diabetic ⁴⁴ , Anti-glycation ⁴⁵
Daidzin	Isoflavone	Anti- diabetic ^{46,47} and anti-obese effects ⁴⁸
Luteolin	Flavone	Anti -adipogenic ^{49, 50}
Kaempferol	Flavonoid	Anti -adipogenic ⁴⁰
Kaempferol-3-O- rutinoside	Flavonol glycoside	Anti- α -glucosidase ⁵¹ , Anti-glycation ⁵² , Anti-adipogenic ⁵³
Naringenin	Flavanones	Anti-diabetic ⁵⁴ , Anti-adipogenic ⁵⁵
Vicenin 2	Flavonoid glycoside	Anti α -glucosidase and anti-glycation properties ⁵⁶
Baicalin	Flavone glycoside	Anti-diabetic ⁵⁷ , Anti-adipogenic ⁵⁸
Calycosin	Isoflavone glycoside	Anti-AGEs ⁵⁹
Corilagin	Polyphenolic compound	Anti-diabetic complications ⁶⁰
Mangiferin	Polyphenolic compound	Anti-diabetic ⁶¹ , Anti-AGEs ⁶² , Anti-adipogenic ⁶³
Chlorogenic acid	Polyphenolic compound	Anti-diabetic and anti-lipidemic effects ^{64,65, 66}
Scopoletin	Phenolic compounds	Anti -hyperglycemic and anti-AGEs ⁶⁷
Apocynin	Phenolic compound	Anti-diabetic ⁶⁸
Ferulic acid	Phenolic acid	Anti-diabetic ⁶⁹ , Anti-adipogenic ⁷⁰
Caffeic acid	Phenolic acids	Anti-diabetic ^{71,72}

Ellagic acid	Phenolic acid	Anti-diabetic ⁷³
3,5-Dicaffeoylquinic acid	Phenolic acids	Anti-diabetic ⁶⁴
Gallic acid	Phenolic Acids	Anti-diabetic ^{74,75} , Anti- α -glucosidase ⁷⁶ , Anti-AGEs ⁷⁷ , anti-obesity ^{78, 79}
Protocatechuic acid	Phenolic Acids	Anti-diabetic ⁷⁵
Vanillic acid	Phenolic acid	Anti- hyperinsulinemia, Anti- hyperglycemia, Anti-hyperlipidemia ⁸⁰
Arginine, Aspartic acid, Glutamic acid, Valine, Leucine, Tyrosine, Isoleucine, Phenylalanine, Tryptophan	Amino Acids	Increase insulin response in Type II diabetes ^{81, 82}
Nicotinic acid	Vitamin B3	Anti-diabetic ⁸³
Riboflavin	Vitamin B2	Anti-diabetic ⁸⁴
Ascorbic acid	Vitamin C	Anti-diabetic and anti-AGEs ⁸⁵ Anti-obesity ⁸⁶
Citric acid	Organic acid	Prevent diabetic complications ⁸⁷ , Anti-obesity ⁸⁸
Fulvic acid	Organic acid	Anti-diabetic effects ⁸⁹
Cinnamic acid	Organic acid	Anti-diabetic effects ⁹⁰ Anti-obesity ⁹¹
α -Linolenic acid	Essential fatty acids	Anti-diabetic effects ⁹² , AGEs inhibition ⁹³
Stearidonic acid	Fatty acid,	Anti-obesity and anti-diabetic effects ^{94,95}
Trichosanic acid	Polyunsaturated fatty acid	Anti-obesity and anti-diabetic effects ⁹⁶
Momordicoside F 2,K & L	Triterpenoid glycosides	Anti-diabetic effects ^{11,12}
Withaferin A	Steroidal lactones	Anti-obesity and anti-diabetic effects ^{97,98,99}
Withanolide A, D, E & V	Steroidal lactones	Increase glucose uptake ¹⁰⁰
Swerchirin	Xanthenes	Anti-hyperglycemic ¹⁰¹
Trillin	Steroidal Saponin	Anti-hyperlipidemic effect ¹⁰²
Diosgenin	Spirostanol saponin	Hypoglycemic and anti-hyperlipidemic effect ^{103, 104}

935 **Table 3. Phenolics and marker compounds in Divya MadhuKalp (DMK) identified by**
 936 **HPLC analysis**

S.N.	Name of Marker Compound	Result (mg/gm)
1	Gallic acid	3.941
2	Vanillic acid	0.577
3	Caffeic acid	0.013
4	Trigonelline	0.319
5	Adenosine	0.063
6	Rutin	0.083
7	Quercetin	0.029
8	Picroside I	0.688
9	Picroside II	1.238
10	Trans-Cinnamic acid	0.162
11	Apigenin	0.004

937